- Home
- ANSC vs ETON Comparison
ANSC vs ETON Comparison
Compare ANSC & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSC
- ETON
- Stock Information
- Founded
- ANSC 2021
- ETON 2017
- Country
- ANSC United States
- ETON United States
- Employees
- ANSC N/A
- ETON N/A
- Industry
- ANSC
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- ANSC
- ETON Health Care
- Exchange
- ANSC Nasdaq
- ETON Nasdaq
- Market Cap
- ANSC 466.6M
- ETON 498.8M
- IPO Year
- ANSC 2023
- ETON 2018
- Fundamental
- Price
- ANSC $11.05
- ETON $18.45
- Analyst Decision
- ANSC
- ETON Strong Buy
- Analyst Count
- ANSC 0
- ETON 3
- Target Price
- ANSC N/A
- ETON $29.67
- AVG Volume (30 Days)
- ANSC 385.1K
- ETON 221.9K
- Earning Date
- ANSC 01-01-0001
- ETON 11-06-2025
- Dividend Yield
- ANSC N/A
- ETON N/A
- EPS Growth
- ANSC N/A
- ETON N/A
- EPS
- ANSC 0.14
- ETON N/A
- Revenue
- ANSC N/A
- ETON $58,181,000.00
- Revenue This Year
- ANSC N/A
- ETON $105.25
- Revenue Next Year
- ANSC N/A
- ETON $40.84
- P/E Ratio
- ANSC $81.39
- ETON N/A
- Revenue Growth
- ANSC N/A
- ETON 85.40
- 52 Week Low
- ANSC $10.38
- ETON $8.24
- 52 Week High
- ANSC $11.12
- ETON $23.00
- Technical
- Relative Strength Index (RSI)
- ANSC 54.21
- ETON 47.47
- Support Level
- ANSC $11.07
- ETON $17.49
- Resistance Level
- ANSC $11.01
- ETON $18.92
- Average True Range (ATR)
- ANSC 0.03
- ETON 0.80
- MACD
- ANSC -0.01
- ETON -0.09
- Stochastic Oscillator
- ANSC 41.67
- ETON 51.89
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.